Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Chemotherapy. Institut Bergonié, Regional Cancer Center, Bordeaux, France

Survival: 20.4 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: France
City/State/Province: Bordeaux
Hospital: Institut Bergonié, Regional Cancer Center
Journal: Link
Date: 12/2007

Patients: This phase II study involved 80 patients with advanced colorectal cancer. They ranged in age from 41 to76 years old. There were about twice as many men in this study as there were women.

Treatment: Patients were divided into two groups or ‘arms’. Patients in arm A were treated with irinotecan and oxaliplatin. Patients in arm B were treated with fluorouracil and either irinotecan or oxaliplatin. These are all chemotherapy drugs. Patients in arm B were also given folinic acid (leucovorin), which is not a chemotherapy drug but is often given with fluoruracil to increase its activity.

Toxicity: Grade 3 and 4 toxicities were slightly more common in patients in arm A (treated with irinotecan and oxaliplatin). Grade ¾ neutropenia occurred in 42.5% of patients in arm A and 32.5% of those in arm B. Febrile neutropenia was reported in 10% of patients from arm A and 5% from arm B. Other toxicities included diarrhea, vomiting, thrombocytopenia, stomatitis, and neurosensory.

Results: The median overall survival was 20.4 months for patients in arm B (treated with fluorouracil, irinotecan/oxaliplatin and folinic acid (leucovorin). The median overall survival in patients treated with irinotecan and oxaliplatin (arm A) was 19 months.

Support: This research was supported with funds from Pfizer and Sanofi Aventis, which market irinotecan as Campto® and Oxaliplatin as Eloxatin®.

Correspondence: Dr. Y. Becouarn

E-mail to a Friend Email Physician More Information